Results 1 to 10 of about 14,599 (198)

Arrhythmia Patterns in Patients on Ibrutinib [PDF]

Frontiers in Cardiovascular Medicine, 2022
Introduction: Ibrutinib, a Bruton's tyrosine kinase inhibitor (TKI) used primarily in the treatment of hematologic malignancies, has been associated with increased incidence of atrial fibrillation (AF), with limited data on its association with other ...
Muhammad Fazal, Ridhima Kapoor, Paul Cheng, Albert J. Rogers, Sanjiv M. Narayan, Paul Wang, Ronald M. Witteles, Alexander C. Perino, Tina Baykaner, June-Wha Rhee   +9 more
doaj   +3 more sources

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

CPT: Pharmacometrics & Systems Pharmacology
Efficacy and safety of ibrutinib 560 mg once daily or placebo combined with bendamustine and rituximab (BR) were assessed in patients with mantle cell lymphoma in a randomized phase 3 study (SHINE).
Per Olsson Gisleskog, Belén Valenzuela, Nicoline Treijtel, Sanjay Deshpande, Todd Henninger, Juan José Perez‐Ruixo   +5 more
doaj   +2 more sources

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells [PDF]

Brazilian Journal of Medical and Biological Research
Despite the widespread use of R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL), the therapeutic efficacy for this disease remains suboptimal, primarily due to the heterogeneity of refractory and/or relapsed diseases.
Fengbo Jin, Limei He, Yingying Chen, Wanlu Tian, Lixia Liu, Ling Ge, Wei Qian, Leiming Xia, Mingzhen Yang   +8 more
doaj   +3 more sources

<i>NOTCH1</i> Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study. [PDF]

EJHaem
ABSTRACT Background Chronic lymphocytic leukemia (CLL) treatment choice remains a challenge in the era of molecular biology and targeted therapy. Methods We conducted a bicentric retrospective analysis of the impact of NOTCH1 mutation according to the treatment of CLL patients in real life.
Haméon C, Houot R, Gyan E, Vallet N, Lachot S, Ganard M, Herault O, De Guibert S, Pastoret C, Dartigeas C.   +9 more
europepmc   +2 more sources

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae

Frontiers in Pharmacology, 2021
Ibrutinib is an orally bioavailable, irreversible selective Bruton’s tyrosine kinase inhibitor that has demonstrated impressive therapeutic effects in patients with B cell malignancies.
Kun Wang, Qiushi Xu, Hanbing Zhong
doaj   +1 more source

Extrahepatic metabolism of ibrutinib [PDF]

Investigational New Drugs, 2020
SummaryIbrutinib is a first-in-class Bruton’s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally their excretion in feces and urine occurs. These metabolites, however, can reach substantial concentrations
Rosalinde Masereeuw, Rolf W. Sparidans, Alfred H. Schinkel, Amer Jamalpoor, Roeland E Wasmann, Roeland E Wasmann, Manoe J. Janssen, Jos H. Beijnen, Jos H. Beijnen, Matthijs J. van Haren, Matthijs J. van Haren, Stephanie van Hoppe, Stephanie van Hoppe, Johannes J.M. Rood   +13 more
openaire   +5 more sources

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

Haematologica, 2021
Ibrutinib is highly active and produces long-term responses in patients with Waldenström macroglobulinemia (WM), but acquired resistance can occur with prolonged treatment.
Joshua N. Gustine, Shayna Sarosiek, Catherine A. Flynn, Kirsten Meid, Carly Leventoff, Timothy White, Maria Luisa Guerrera, Lian Xu, Amanda Kofides, Nicholas Tsakmaklis, Manit Munshi, Maria Demos, Christopher J. Patterson, Xia Liu, Guang Yang, Zachary R. Hunter, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +18 more
doaj   +1 more source

Ibrutinib-induced cardiomyopathy [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2019
The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital with new-onset atrial fibrillation and symptomatic ...
Htay Htay Kyi, Yazan Zayed, Samer Al Hadidi   +2 more
openaire   +4 more sources

Simultaneous Determination of Orelabrutinib, Zanubrutinib, Ibrutinib and Its Active Metabolite in Human Plasma Using LC-MS/MS

Molecules, 2023
Ibrutinib, orelabrutinib, and zanubrutinib are all Bruton’s tyrosine kinase inhibitors, which have greatly improved the treatment of B-cell malignancies. In this study, an LC-MS/MS method was developed and validated for the determination of orelabrutinib,
Lu-Ning Sun, Yang Zhao, Zhou-Yi Qian, Xiang-Long Chen, Hong Ma, Yu-Jiao Guo, Hao Shen, Yong-Qing Wang   +7 more
doaj   +1 more source

Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry

Pathology and Oncology Research, 2022
Background: Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse.
Ferenc Takács, Ferenc Takács, Lili Kotmayer, Ágnes Czeti, Gábor Szalóki, Tamás László, Gábor Mikala, Ágnes Márk, András Masszi, Péter Farkas, Márk Plander, Júlia Weisinger, Judit Demeter, Sándor Fekete, László Szerafin, Beáta Margit Deák, Erika Szaleczky, Adrienn Sulák, Zita Borbényi, Gábor Barna   +19 more
doaj   +1 more source